Atara Book Value Per Share vs Capex To Depreciation Analysis

ATRA Stock

USD 11.47 0.86 8.11%

Atara Biotherapeutics financial indicator trend analysis is way more than just evaluating Atara Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Atara Biotherapeutics is a good investment. Please check the relationship between Atara Biotherapeutics Book Value Per Share and its Capex To Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

Book Value Per Share vs Capex To Depreciation

Book Value Per Share vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Atara Biotherapeutics Book Value Per Share account and Capex To Depreciation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Atara Biotherapeutics' Book Value Per Share and Capex To Depreciation is 0.47. Overlapping area represents the amount of variation of Book Value Per Share that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Atara Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Atara Biotherapeutics' Book Value Per Share and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Book Value Per Share of Atara Biotherapeutics are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Book Value Per Share i.e., Atara Biotherapeutics' Book Value Per Share and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from Atara Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Atara Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 6.24, whereas Selling General Administrative is forecasted to decline to about 47.3 M.

	2021	2022	2023	2024 (projected)
Net Interest Income	367K	2.0M	944K	896.8K
Interest Income	367K	2.0M	4.8M	3.2M

Net Interest Income Interest Income

Atara Biotherapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Retained Earnings Total Equity
Total Assets		0.66	0.53	0.77	0.31	0.76	-0.63	-0.56	0.62	0.82	0.75	0.32	0.71	0.92	0.63	0.32	0.3	0.93	0.75	0.43	0.72	0.95	0.69	0.7	0.87	-0.64
Other Current Liab	0.66		0.92	0.09	0.87	0.8	-0.07	-0.93	0.49	0.47	0.81	0.82	0.48	0.38	0.94	-0.16	0.81	0.66	0.88	0.91	0.82	0.48	0.88	0.39	0.42	-0.93
Total Current Liabilities	0.53	0.92		-0.11	0.92	0.71	0.07	-0.97	0.49	0.33	0.72	0.81	0.31	0.2	0.97	-0.21	0.8	0.57	0.83	0.95	0.76	0.3	0.85	0.3	0.36	-0.93
Total Stockholder Equity	0.77	0.09	-0.11		-0.35	0.38	-0.82	0.06	0.39	0.71	0.37	-0.3	0.59	0.94	0.02	0.55	-0.32	0.69	0.29	-0.23	0.32	0.9	0.21	0.66	0.78	-0.05
Other Liab	0.31	0.87	0.92	-0.35		0.56	0.34	-0.93	0.3	0.12	0.58	0.96	0.17	-0.04	0.91	-0.34	0.93	0.32	0.72	0.97	0.61	0.08	0.77	-0.01	0.06	-0.88
Property Plant And Equipment Net	0.76	0.8	0.71	0.38	0.56		-0.35	-0.78	0.73	0.65	1.0	0.58	0.55	0.57	0.79	0.25	0.56	0.84	0.9	0.67	0.99	0.63	0.87	0.76	0.5	-0.84
Net Debt	-0.63	-0.07	0.07	-0.82	0.34	-0.35		-0.06	-0.44	-0.89	-0.33	0.33	-0.77	-0.79	0.03	-0.23	0.23	-0.67	-0.24	0.16	-0.29	-0.75	-0.16	-0.64	-0.63	0.05
Retained Earnings	-0.56	-0.93	-0.97	0.06	-0.93	-0.78	-0.06		-0.5	-0.38	-0.8	-0.89	-0.38	-0.24	-0.99	0.17	-0.87	-0.61	-0.9	-0.97	-0.82	-0.35	-0.92	-0.29	-0.31	0.99
Accounts Payable	0.62	0.49	0.49	0.39	0.3	0.73	-0.44	-0.5		0.6	0.73	0.28	0.37	0.51	0.5	0.2	0.31	0.6	0.6	0.42	0.7	0.53	0.55	0.76	0.38	-0.56
Cash	0.82	0.47	0.33	0.71	0.12	0.65	-0.89	-0.38	0.6		0.65	0.13	0.91	0.82	0.41	0.1	0.22	0.87	0.62	0.29	0.61	0.84	0.55	0.65	0.66	-0.49
Non Current Assets Total	0.75	0.81	0.72	0.37	0.58	1.0	-0.33	-0.8	0.73	0.65		0.6	0.55	0.55	0.8	0.23	0.58	0.83	0.91	0.69	0.99	0.62	0.88	0.74	0.48	-0.86
Non Currrent Assets Other	0.32	0.82	0.81	-0.3	0.96	0.58	0.33	-0.89	0.28	0.13	0.6		0.22	0.0	0.86	-0.3	0.96	0.31	0.73	0.93	0.61	0.11	0.77	-0.05	-0.02	-0.87
Other Assets	0.71	0.48	0.31	0.59	0.17	0.55	-0.77	-0.38	0.37	0.91	0.55	0.22		0.71	0.39	-0.14	0.27	0.79	0.58	0.31	0.51	0.74	0.53	0.43	0.57	-0.48
Cash And Short Term Investments	0.92	0.38	0.2	0.94	-0.04	0.57	-0.79	-0.24	0.51	0.82	0.55	0.0	0.71		0.32	0.39	-0.01	0.82	0.56	0.1	0.52	0.99	0.49	0.68	0.84	-0.35
Common Stock Total Equity	0.63	0.94	0.97	0.02	0.91	0.79	0.03	-0.99	0.5	0.41	0.8	0.86	0.39	0.32		-0.09	0.83	0.66	0.9	0.94	0.82	0.42	0.91	0.32	0.41	-0.97
Common Stock Shares Outstanding	0.32	-0.16	-0.21	0.55	-0.34	0.25	-0.23	0.17	0.2	0.1	0.23	-0.3	-0.14	0.39	-0.09		-0.39	0.29	0.01	-0.31	0.22	0.36	-0.02	0.46	0.42	0.15
Non Current Liabilities Total	0.3	0.81	0.8	-0.32	0.93	0.56	0.23	-0.87	0.31	0.22	0.58	0.96	0.27	-0.01	0.83	-0.39		0.31	0.71	0.95	0.59	0.1	0.74	-0.02	-0.04	-0.86
Other Current Assets	0.93	0.66	0.57	0.69	0.32	0.84	-0.67	-0.61	0.6	0.87	0.83	0.31	0.79	0.82	0.66	0.29	0.31		0.79	0.46	0.81	0.86	0.73	0.75	0.82	-0.68
Other Stockholder Equity	0.75	0.88	0.83	0.29	0.72	0.9	-0.24	-0.9	0.6	0.62	0.91	0.73	0.58	0.56	0.9	0.01	0.71	0.79		0.81	0.92	0.64	0.99	0.51	0.46	-0.94
Total Liab	0.43	0.91	0.95	-0.23	0.97	0.67	0.16	-0.97	0.42	0.29	0.69	0.93	0.31	0.1	0.94	-0.31	0.95	0.46	0.81		0.71	0.21	0.84	0.14	0.16	-0.94
Property Plant And Equipment Gross	0.72	0.82	0.76	0.32	0.61	0.99	-0.29	-0.82	0.7	0.61	0.99	0.61	0.51	0.52	0.82	0.22	0.59	0.81	0.92	0.71		0.59	0.9	0.72	0.46	-0.86
Total Current Assets	0.95	0.48	0.3	0.9	0.08	0.63	-0.75	-0.35	0.53	0.84	0.62	0.11	0.74	0.99	0.42	0.36	0.1	0.86	0.64	0.21	0.59		0.58	0.67	0.84	-0.45
Common Stock	0.69	0.88	0.85	0.21	0.77	0.87	-0.16	-0.92	0.55	0.55	0.88	0.77	0.53	0.49	0.91	-0.02	0.74	0.73	0.99	0.84	0.9	0.58		0.44	0.39	-0.95
Property Plant Equipment	0.7	0.39	0.3	0.66	-0.01	0.76	-0.64	-0.29	0.76	0.65	0.74	-0.05	0.43	0.68	0.32	0.46	-0.02	0.75	0.51	0.14	0.72	0.67	0.44		0.63	-0.37
Net Tangible Assets	0.87	0.42	0.36	0.78	0.06	0.5	-0.63	-0.31	0.38	0.66	0.48	-0.02	0.57	0.84	0.41	0.42	-0.04	0.82	0.46	0.16	0.46	0.84	0.39	0.63		-0.34
Retained Earnings Total Equity	-0.64	-0.93	-0.93	-0.05	-0.88	-0.84	0.05	0.99	-0.56	-0.49	-0.86	-0.87	-0.48	-0.35	-0.97	0.15	-0.86	-0.68	-0.94	-0.94	-0.86	-0.45	-0.95	-0.37	-0.34

Click cells to compare fundamentals

Atara Biotherapeutics Account Relationship Matchups

Atara Biotherapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	342.9M	588.1M	468.1M	376.4M	165.5M	302.7M
Other Current Liab	5.7M	40.3M	44.9M	50.4M	48.5M	51.0M
Total Current Liabilities	36.7M	82.9M	105.8M	78.9M	142.2M	149.3M
Total Stockholder Equity	290.8M	462.3M	279.6M	126.6M	(99.2M)	(94.3M)
Other Liab	1.0M	29.7M	57.2M	109.2M	125.5M	131.8M
Property Plant And Equipment Net	68.2M	62.8M	79.9M	74.3M	58.8M	42.2M
Net Debt	(60.2M)	(187.4M)	(80.6M)	(21.2M)	32.0M	33.6M
Retained Earnings	(818.0M)	(1.1B)	(1.5B)	(1.7B)	(2.0B)	(1.9B)
Accounts Payable	8.0M	7.1M	17.4M	6.9M	3.7M	6.1M
Cash	74.3M	200.4M	106.1M	92.9M	25.8M	24.5M
Non Current Assets Total	70.0M	64.8M	83.5M	81.3M	63.6M	44.3M
Non Currrent Assets Other	567K	827K	2.4M	7.0M	4.8M	5.1M
Other Assets	1.8M	14.3M	3.6M	7.0M	1.0	0.95
Cash And Short Term Investments	259.1M	500.7M	371.1M	242.8M	51.7M	49.1M
Common Stock Total Equity	6K	8K	9K	10K	11.5K	12.1K
Common Stock Shares Outstanding	51.3M	3.0M	3.7M	4.1M	4.2M	4.0M
Liabilities And Stockholders Equity	342.9M	588.1M	468.1M	376.4M	165.5M	302.7M
Non Current Liabilities Total	15.4M	42.9M	82.7M	170.9M	122.5M	128.6M
Other Current Assets	13.9M	21.4M	12.6M	10.5M	6.3M	8.6M
Other Stockholder Equity	1.1B	1.6B	1.7B	1.8B	1.9B	952.6M
Total Liab	52.2M	125.8M	188.5M	249.8M	264.7M	278.0M
Property Plant And Equipment Gross	68.2M	62.8M	79.9M	74.3M	74.7M	43.7M
Total Current Assets	273.0M	523.3M	384.6M	295.1M	101.9M	96.8M
Accumulated Other Comprehensive Income	220K	296K	(368K)	(2.1M)	(204K)	(214.2K)
Common Stock	6K	8K	9K	10K	11K	5.7K
Property Plant Equipment	54.2M	50.5M	79.9M	6.3M	7.2M	6.9M
Net Tangible Assets	290.8M	462.3M	279.6M	126.6M	145.6M	287.0M
Retained Earnings Total Equity	(818.0M)	(1.1B)	(1.5B)	(1.7B)	(1.5B)	(1.4B)
Short Term Investments	184.8M	300.3M	265.0M	149.9M	25.9M	24.6M
Capital Surpluse	1.1B	1.6B	1.7B	1.8B	2.1B	1.1B
Non Current Liabilities Other	15.4M	42.9M	1.5M	170.9M	39.3M	36.2M
Short Long Term Debt Total	14.1M	13.0M	25.5M	71.7M	57.9M	60.8M
Current Deferred Revenue	21.5M	33.5M	40.8M	8M	77.8M	81.7M
Net Invested Capital	290.8M	462.3M	279.6M	126.6M	(99.2M)	(94.3M)
Net Working Capital	236.2M	440.4M	278.8M	216.2M	(40.4M)	(38.3M)
Short Term Debt	1.6M	2.0M	2.8M	13.6M	12.2M	12.8M
Capital Stock	6K	8K	9K	10K	11K	9.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:

How To Invest In Atara

Details

Is Atara Stock a good investment?

Details

What is Atara Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(25.32)

Revenue Per Share

12.263

Quarterly Revenue Growth

28.927

Return On Assets

(0.57)

Return On Equity

(20.15)

The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Atara Book Value Per Share vs Capex To Depreciation Analysis

Book Value Per Share vs Capex To Depreciation

Book Value Per Share vs Capex To Depreciation Correlation Analysis

Correlation Coefficient

Book Value Per Share

Capex To Depreciation

Atara Biotherapeutics fundamental ratios Correlations

Atara Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Atara Biotherapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Retained Earnings Total Equity	+ 0.99	Retained Earnings
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock	+ 0.99	Other Stockholder Equity

Common Stock Total Equity	- 0.99	Retained Earnings
Retained Earnings Total Equity	- 0.97	Common Stock Total Equity
Total Liab	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Retained Earnings Total Equity	- 0.95	Common Stock
Retained Earnings Total Equity	- 0.94	Total Liab